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Abstract
Aberrant activation of the PI3K/mTOR-pathway is a common feature of many cancers and an 
attractive target for therapy, but resistance inevitably evolves is as the case for any cancer cell 
targeted therapy. In animal tumor models, chronic inhibition of PI3K/mTOR initially inhibits 
tumor growth, but over time, tumor cells escape inhibition. In this study, we identified a context-
dependent mechanism of escape whereby tumor cells upregulated the proto-oncogene 
transcriptional regulators c-MYC and YAP1. This mechanism was dependent on both constitutive 
ERK activity as well as inhibition of the stress kinase p38. Inhibition of p38 relieved proliferation 
arrest and allowed upregulation of MYC and YAP through stabilization of CREB. These data 
provide new insights into cellular signaling mechanisms that influence resistance to PI3K/mTOR 
inhibitors. Furthermore, they suggest that therapies that inactivate YAP or MYC or augment p38 
activity could enhance the efficacy of PI3K/mTOR inhibitors.
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Introduction
The PI3K/mTOR (Phosphatidylinositol-4,5-bisphosphate-3-kinase/mechanistic-Target-of-
Rapamycin) pathway is a major growth signaling pathway that regulates a wide variety of 
cellular processes, such as protein, nucleotide and lipid synthesis (1). Mutations in several 
oncogenes or loss of tumor suppressors lead to deregulated PI3K/mTOR-signaling in tumors 
(for reviews see (2, 3)), making it an attractive target for therapy. Although single agent 
inhibition of PI3K/mTOR typically leads to cytostasis, it has not led to durable response 
rates, rarely inducing tumor cell death or shrinkage of solid tumors (reviewed in (4)). Under 
cytostasis, tumors can relapse due to emergence of resistant cells that escape proliferative 
suppression through genetic or epigenetic mechanisms.
Upregulation of receptor tyrosine kinases (RTKs) (5–10) is a known resistance mechanism 
that allows cancer cells to survive PI3K/mTOR inhibition. Upregulation of RAS/MEK/ERK-
pathway can also promote resistance to PI3K/mTOR inhibitors (6, 11, 12). Other reported 
mechanisms include modulation of RSK3/4 (13), c-MYC (14, 15), β-catenin (16), eIF4E 
(15, 17), or deregulation of 4EBP proteins (18–20). Although these alterations promote 
survival, the mechanism by which tumor cells overcome proliferation arrest induced by 
PI3K/mTOR inhibitors is not well understood. Here, we identify upregulation of c-MYC and 
yes-associated protein (YAP1) as a resistance mechanism that allows proliferation under 
chronic PI3K/mTOR inhibition. MYC and YAP upregulation is context-dependent, 
occurring in an activated RAS/ERK-background, and requires suppression of the stress-
activated p38 MAPK (MAPK14).
Materials and Methods
Antibodies and Reagents
Rapamycin (gift from Dr. Blenis), BEZ235 (Axon-Medchem) and Torin1 (Tocris-
Bioscience) were dissolved in DMSO and used at indicated concentrations. BEZ235 was 
used at 0.5μM except where noted differently. SB203580/SB202190 (Cell Signaling 
Technologies) were used at 5μM concentration, and cells were pre-incubated with the 
inhibitor 24h. UO126 (Sigma) was used at 10μM. MK2206, BKM120, GDC0941 (Selleck) 
were all used at 250nM. All antibodies are described in supplemental materials.
Plasmids/shRNAs
shRNAs were obtained from RNAi Consortium (clone IDs from Open BioSystems). pLKO 
MYC shB5 (TRCN0000039639), MYC shB6 (TRCN0000039640) and shB8 
(TRCN0000039642), YAP1 shF5 (TRCN0000107265) and shF8 (TRCN0000107268), 
KRAS shA8 (TRCN0000033261), shA9 (TRCN0000033262) and pLKO scrambled were 
used in shRNA experiments. Plasmids for over-expression of MYC and YAP1 were pBABE 
YAP1 (Addgene#15682), pWZL MYC (Addgene#10674) and CREB1 WT in pQCXIB. 
pcDNA-p38CA (p38/Mapk14) was a kind gift from Dr. Aguirre-Ghiso.
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RPPA Analysis
RPPA sample preparation, normalization of data points, and analysis were performed as 
previously described (21). Cell lysates were arrayed on slides, incubated with antibodies and 
quantified. Differentially expressed proteins and phospho-proteins were identified using t-
test or ANOVA and p<0.05 threshold. Heatmaps were generated using Cluster3.0 and Java 
TreeView1.1.1. Proteins were ordered by the rank-sum of the normalized values.
Cell culture
MCAS, OVCAR5, OvCa432, MDA-MB-468, MCF7 and TOV21G lines were from Dr. 
Slamon (UCLA) between 2008 and 2012 and validated by short tandem repeat (STR) 
profiling. HeLA, HCT116 and cancer lines in Figure 6 were from Dr. Sabatini (Whitehead/
MIT) obtained in 2013, and 19 of the 27 lines were validated by STR at the time. HeLa, 
A431, DLD1, DU-145, PC3, BT549, SK-MEL-28, SW620 and S462 have not been profiled. 
Jeko is of unknown lineage. 3D experiments were performed as described before [8]. 
Detailed description is in supplemental methods. Lentiviral vectors encoding shRNAs in 
pLKO-plasmids were generated in 293T cells and retroviruses were generated in 293GPGs 
according to standard protocol (22).
Xenograft experiments
500.000 (HCT116) or million cells (OVCAR5) in 1:1 mix of PBS:Matrigel were injected 
subcutaneously into two flanks of ~24g 10–12 week-old female NOD.CB17-Prkdcscid/J 
mice (Jackson labs). Once tumors became palpable (~250mm3), 12d (HCT116) or 28d 
(OVCAR5), mice were randomized to groups of five for each treatment group (20 animals in 
total). Five animals per group were calculated to give sufficient statistical power for the 
purpose of this experiment. Drug was administered daily intra-peritoneally. GNE493 
(Genentech) (10mg/kg) was dissolved in 0.5% methylcellulose/0.2% Tween-80. Tumors 
were harvested on 11–13d post-treatment. All mouse studies were conducted through 
Institutional Animal Care and Use Committee (IACUC)-approved animal protocols 
(#04004) in accordance with Harvard Medical School institutional guidelines.
Immunofluorescence and microscopy
3D spheroids were fixed, stained and imaged as previously described (23). Paraffin 
embedded tumor sections were unmasked by pH6 citrate-buffer and probed overnight with 
primary antibodies. Secondary antibodies were with Alexa-488, and −568 (Invitrogen). Cells 
were imaged with confocal microscopy, more detailed description is in supplemental 
methods.
Western blot
Cells were harvested for Western in RIPA-buffer supplemented with protease and 
phosphatase inhibitors and MG132 (Sigma). Lysates were boiled in 1× sample buffer for 
5min, resolved by 4–20% SDS-PAGE gradient gels, transferred PVDF membranes 
(Whatman), blocked with 5% BSA-TTBS, and probed by primary antibodies o/n. 
Membranes were probed with secondary antibodies linked to horseradish peroxidase.
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Results
We previously showed using 3D spheroid cultures that treatment of matrix-adherent cancer 
cells with PI3K/mTOR inhibitors results in inhibition of cell proliferation but rarely in cell 
death (8). To model progression under conditions of chronic PI3K/mTOR inhibition in 3D, 
we cultured MCAS tumor cells under chronic exposure to the dual PI3K/mTOR inhibitor, 
BEZ235. Cells were cultured in reconstituted basement membrane proteins (3D), during 
which time the drugs and media were replenished every four days. Due to the sequestration 
of BEZ235 in 3D cultures, we used BEZ235 at 0.5–1μM concentration to fully inhibit the 
pathway (Supplemental Fig. 1A). MCAS cells initially displayed cytostasis in the presence 
of BEZ235. However, after one year of chronic exposure, proliferative outgrowths emerged 
(Fig. 1A lower panel), whereas control cells cultured in 3D for the same amount of time in 
the absence of drug remained sensitive to BEZ235 (Fig. 1A, top panel). After proliferation 
became apparent, the resistant cells (MCAS-R) were passaged by trypsinization every two 
weeks and maintained constitutively as 3D cultures in the presence of BEZ235, and the 
sensitive cells were maintained in DMSO (MCAS-S).
To verify that the MCAS-R outgrowths were due to proliferation, we stained for the 
proliferation marker Ki67 in 3D (Fig. 1B), and analyzed cell numbers in 3D at indicated 
timepoints (Fig. 1C and D). Although the baseline proliferation rate of vehicle-treated 
MCAS-R cells was lower than that of MCAS-S cells (Fig. 1C), the MCAS-R cells displayed 
significant proliferative advantage in the presence of BEZ235 (Fig. 1D, Tukey HSD p<0.01). 
This effect was not limited to BEZ235, as MCAS-R cells also proliferated in the presence of 
a structurally distinct mTOR inhibitor, Torin1 (Fig. 1D, Tukey p<0.05), and with 
combination of BEZ235 and Rapamycin (Fig. 1D, Tukey p<0.01). To eliminate altered drug 
metabolism or efflux as potential mechanisms of resistance, we evaluated whether BEZ235, 
Torin and Rapamycin still inhibit mTOR target molecules (p-S6, p-AKT and p-4EBP1). 
Indeed, all inhibitors suppressed phosphorylation of these proteins (Fig. 1E). However, 
MCAS-R cells consistently displayed slightly higher levels of translation regulator 4EBP 
and phospho-4EBP1 under BEZ235-treated conditions. This is not surprising given previous 
reports demonstrating that minimal recovery of cap-dependent translation is needed for 
mTOR inhibitor resistance (15, 18–20).
The simultaneous emergence of MCAS-R cell outgrowths in several spheroids suggests that 
this is not a rare genetic event, but a time-dependent adaptation to chronic PI3K/mTOR 
inhibition. Consistent with this hypothesis, full exome-sequencing (>830× coverage/cell 
line) failed to identify non-synonymous or splicing variants that are discordant between 
MCAS-R and MCAS-S cells (24) (NCBI Sequence-Read-Archive Accession #SRP057514). 
Although epigenetic or non-exon alterations that might contribute to resistance cannot be 
ruled out, this data, together with the evidence that MCAS-R cells revert to drug-sensitive 
state after 16 weeks of drug-free culture (Supplemental Fig. 1B), led us to investigate 
alternative mechanisms of resistance. To examine a broad array of signaling pathways that 
could mediate resistance, we performed reverse phase protein arrays (RPPA) on lysates from 
MCAS-S and MCAS-R cells treated in 3D cultures with DMSO or BEZ235. We then 
evaluated which proteins were differentially altered under any condition (Fig. 2A). Signals 
from several proteins or phospho-proteins differed significantly in BEZ235-treated MCAS-R 
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and MCAS-S cells, however many of these also differed under basal DMSO-treated 
conditions (Fig. 2A, Supplemental Fig. 1C). 58 proteins were significantly differentially 
altered in expression or phosphorylation by BEZ235-treatment in one of the two lines (Fig. 
2B, p<0.05 BEZ235-treated MCAS-R vs. BEZ235-treated MCAS-S cells). Two proteins 
previously reported to promote resistance to PI3K/mTOR inhibitors, MYC and eIF4E, were 
significantly upregulated by BEZ235 treatment in MCAS-R cells relative to MCAS-S cells 
(Fig. 2A and B), but were not significantly changed at baseline. Similarly, several other 
proteins, including EGFR, paxillin, NF2, Cyclin E, caveolin1 and YAP were also 
differentially upregulated by BEZ235 in MCAS-R cells with minimal differences at baseline 
(Fig. 2B). The RPPA results for several upregulated proteins were validated by Western blot 
(Fig. 2C and Supplemental Fig. 1D).
Since MYC and YAP, the Hippo-pathway effector (for reviews (25, 26)), are well-
recognized regulators of cell proliferation, we focused on these two proteins and examined 
whether their modulation would be sufficient to impact the sensitivity to BEZ235. We first 
evaluated whether other structurally distinct PI3K/mTOR (GNE493) or mTOR (Torin1) 
inhibitors induce similar changes as observed with BEZ235 in 3D and observed upregulation 
in both YAP and MYC (Supplemental Fig. 1E). We next addressed whether overexpression 
of YAP and/or MYC in the parental MCAS cells would be sufficient to overcome 
proliferative suppression induced by BEZ235 under standard monolayer culture conditions 
(2D). Although overexpression of either YAP or MYC alone promoted growth in the 
presence of BEZ235 (Fig. 2D and Supplemental Fig. 2A, p<0.01), concurrent 
overexpression of MYC and YAP significantly enhanced proliferation of MCAS cells 
compared to overexpression of either one alone (Fig. 2D, p<0.01).
We also examined whether the ability of MCAS-R cells to evade proliferative suppression 
induced by BEZ235 was dependent on YAP or MYC. Although shRNA knockdown of YAP 
or MYC resulted in significant proliferation inhibition of BEZ235-treated MCAS-R cells in 
3D (Supplemental Fig. 2B and C), knockdown of either one of these genes also impaired 
proliferation in the DMSO control cells, indicating that MYC and YAP are required for 
proliferation under 3D culture conditions. Thus, we were unable to assess the effects of YAP 
or MYC knockdown on BEZ235 resistance in MCAS-R cells in 3D. Interestingly, 
knockdown of YAP did not significantly impair proliferation of DMSO-treated parental 
MCAS cells grown as 2D cultures (Supplemental Fig. 2D). Since MYC has previously been 
reported to promote resistance to PI3K/mTOR inhibitors (14, 15), we examined the 
requirement for YAP in MYC overexpression-induced BEZ235 resistance in 2D. shRNA 
knockdown of endogenous YAP significantly sensitized MYC-overexpressing parental 
MCAS cells to BEZ235-induced proliferative suppression (Fig. 2E and Supplemental Fig. 
2E, p<0.01), indicating that the ability of MYC to drive proliferation under conditions of 
PI3K/mTOR inhibition is supported by endogenous YAP.
Endogenous YAP levels were unaffected by MYC expression, and vice versa (Supplemental 
Fig. 2F), indicating that co-dependence of these proteins is not due to direct regulation of 
one protein by the other. Therefore we focused on identifying other potential upstream 
mechanisms by which these proteins could be coordinately upregulated during the 
establishment of resistance. The p38/MAPK, which is known to regulate stress responses 
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when activated by phosphorylation (reviewed in (27)), was also identified by RPPA analysis 
as differentially regulated by BEZ235 in MCAS-R and MCAS-S cells (Fig. 2A and B). 
Given the known role of p38 in regulating response to cellular stress and cell cycle arrest 
(28), and its role in regulating YAP levels (29, 30), we examined whether it could contribute 
to enhanced proliferation of MCAS-R cells in 3D. Of note, although BEZ235 treatment 
induced activation of p38 (phosphorylation of T180/T182) in both MCAS-R and MCAS-S 
cells in 3D (Fig. 2A and B, Fig. 3A), MCAS-R cells displayed significantly less induction of 
phospho-p38 than MCAS-S cells (Figs. 2A and B, 3A), raising the possibility that reduced 
activation of p38 could contribute to the increased proliferative capacity of MCAS-R cells in 
the presence of BEZ235.
To examine the contribution of p38 to BEZ235 sensitivity, we inhibited p38 with SB203580 
in parental MCAS cells treated with BEZ235 in 2D. This treatment significantly enhanced 
proliferation (p<0.05) of BEZ235-treated cells, but had no effect on proliferation in the 
absence of BEZ235 (Fig. 3B and C, and Supplemental Fig. 3A). After 14d treatment, few 
cells remained in the BEZ235-treated samples, whereas small colonies of proliferating cells 
were apparent in samples treated with combined BEZ235 and p38 inhibitor (Fig. 3B). 
Combination treatment induced upregulation of YAP and MYC in parental MCAS cells 
(Fig. 3D and Supplemental Fig. 3B), as did BEZ235 treatment in combination with a 
structurally distinct p38 inhibitor (SB202190) (Supplemental Fig. 3C), indicating that in the 
presence of BEZ235, inhibition of p38 is sufficient to induce upregulation of YAP and MYC 
and result in proliferation.
Given that PI3K inhibition induces DNA damage (31, 32), a known regulator of p38 (27), 
we examined potential markers of DNA damage in the RPPA. We found that expression of 
XRCC1, Mre11 and X53BP1 was induced in the BEZ235-treated MCAS-S cells, whereas 
these proteins were all down-regulated in MCAS-R cells (Supplemental Fig. 3D). We next 
assessed the extent of DNA damage by phospho-γH2AX immunofluorescence. BEZ235-
treated MCAS-S cells displayed significantly more phospho-γHA2X-positive foci compared 
to MCAS-R cells (Supplemental Fig. 3E), raising the possibility that DNA damage induced 
by PI3K/mTOR inhibition drives activation of p38 in MCAS-S cells, and that, through an 
unknown mechanism, this stress is resolved in MCAS-R cells.
To determine which node of the PI3K/mTOR-pathway regulates p38-activation, we treated 
parental MCAS cells in 2D with Torin1 (mTORi), BEZ235 (PI3Ki/mTORi), MK2206 
(AKTi), GDC0941 (PI3Ki), or BKM120 (PI3Ki). Activation of p38 was not detected after 
short-term treatment (5min), indicating that a long-term inhibition is required for p38 
activation. After 72h incubation, mTOR inhibition (BEZ235 or Torin1) induced robust 
phospho-p38, whereas AKT and PI3K inhibition induced it to a lesser extent (Supplemental 
Fig. 3F). A detailed time-course demonstrated that phospho-p38 was detectable after 3h 
incubation and reached a peak after 72h (Supplemental Fig. 3F). These data suggest that p38 
activation in response to mTOR inhibition is not mediated by an acute kinase/phosphatase-
cascade, but rather a mechanism that involves prolonged mTOR inhibition.
Interestingly, inhibition of p38 stabilizes cAMP response element-binding protein (CREB), 
which has been shown to positively regulate YAP levels (29, 30). To address whether CREB 
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could contribute to YAP upregulation in MCAS-R cells in 3D, we analyzed total CREB 
levels in the MCAS lines after BEZ235 treatment. We detected a marked increase in CREB 
protein levels in BEZ235-treated MCAS-R cells, whereas only a slight increase in MCAS-S 
cells was observed (Fig. 3E). Prolonged BEZ235 treatment (14d) of the parental MCAS cell 
line in 2D led to a marked increase in phospho-p38 and a decrease in CREB levels, and 
conversely p38 inhibition restored CREB levels in the parental BEZ235-treated cells (Fig. 
3D and Supplemental Fig. 3C). These results are consistent with a model in which p38 
activity, which is induced by BEZ235, suppresses CREB protein expression in the sensitive/
parental cells.
To assess whether an increase in CREB protein levels is sufficient to promote resistance to 
mTOR inhibitors, we overexpressed wild-type CREB in parental MCAS cells and assessed 
proliferation in 2D. Overexpression of CREB significantly (p<0.005) increased the 
proliferation of BEZ235-treated parental MCAS cells and induced upregulation of YAP and 
MYC but only under BEZ235 treatment (Fig. 3F and G and Supplemental Fig. 3G). These 
results suggest that reduced p38 activation contributes both to the increase in proliferation 
and the upregulation of MYC, YAP and CREB levels observed in BEZ235-treated MCAS-R 
cells.
To evaluate the requirement for YAP downstream of CREB, we knocked down YAP in 
CREB-overexpressing parental MCAS cells. YAP depletion prevented proliferation in the 
presence of BEZ235, suggesting that YAP is required for CREB-induced proliferation under 
conditions of PI3K/mTOR inhibition (Fig. 3H). Furthermore, a comparative analysis of 
CREB-amplified versus non-amplified high-grade serous ovarian tumors revealed that YAP 
protein expression is significantly increased in tumors harboring CREB amplification 
(p=0.031, Fig. 3I). We also noted a significant positive correlation between CREB and YAP 
mRNA expression in colon, kidney, breast and liver tumors, suggesting that these proteins 
could be functionally coupled in patient tumors (Fig. 3J).
To assess whether YAP and MYC are required for resistance to PI3K/mTOR inhibitors in 
other cell lines, we analyzed a wide panel of tumor cell lines and identified three resistant 
lines that display continuous proliferation in the presence of BEZ235: the colon cancer cell 
line HCT116, and the ovarian cancer lines OVCAR5 and OvCa432 (Fig. 4A and 
Supplemental Fig. 4A and B). Notably, upregulation of YAP after six-day BEZ235 treatment 
was specifically observed in all resistant cell lines, and upregulation of MYC in HCT116 
and OVCAR5 cells, but not in the sensitive lines (HeLa, MCF7 and TOV21G) (Fig. 4B). 
Although CREB upregulation was not detected following BEZ235 treatment, high basal 
CREB levels were specifically observed in the resistant cell lines (Fig. 4C). Furthermore, 
shRNA knockdown of either MYC or YAP significantly retarded proliferation in BEZ235-
treated HCT116 cells (p<0.001), the most resistant cell line we identified (Fig. 4D and 
Supplemental Fig. 4C). We also found that transient overexpression of constitutively active 
p38α significantly reduced the viability of HCT116 cells two days after BEZ235 treatment 
(p<0.005, Fig. 4E), suggesting that activation of p38 also sensitizes intrinsically resistant 
cells to PI3K/mTOR inhibition.
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To assess whether PI3K/mTOR inhibition induces YAP and MYC upregulation in vivo, 
NOD-SCID mice were subcutaneously injected with resistant HCT116 and OVCAR5 cells 
and, once tumors were formed, were treated with vehicle or PI3K/mTOR inhibitor GNE493 
(10mg/kg) (33). GNE493 treatment significantly increased intensity of both YAP (Fig. 5A 
and C) and MYC staining (Fig. 5B and D) in the Ki67-positive areas of HCT116 and 
OVCAR5 tumors (Fig. 5E), indicating that both YAP and MYC are upregulated in 
proliferating tumor cells in vivo under PI3K/mTOR inhibition.
To determine whether resistance to mTOR inhibitors is correlated with mutational status, we 
performed a proliferation analysis on a panel of cancer cell lines in the presence of mTOR 
inhibition (Fig. 6A). The proliferation index and resistance to mTOR inhibitors correlated 
with the mutational status of the KRAS/ERK-pathway (Fig. 6B). Of the resistant cell lines 
we previously identified, MCAS, HCT116, OVCAR5 and OVCA432 harbor activating 
mutations in KRAS (G12V). Consistent with these results, knockdown of KRAS sensitized 
HCT116 cells to PI3K/mTOR inhibition (Fig. 6C). Moreover, combined treatment of 
HCT116 cells with BEZ235 and 10μM MEK inhibitor (UO126) prevented upregulation of 
MYC and YAP, suggesting that RAS/MEK/ERK-pathway is required for MYC and YAP 
upregulation (Fig. 6D).
A role for ERK in mediating resistance to PI3K inhibitors has been reported (6, 11, 12). 
Given our data showing a correlation between PI3K/mTOR inhibitor resistance and KRAS 
mutational status, and that MYC and YAP upregulation was blocked by inhibition of the 
MEK/ERK-pathway, we probed for ERK activation in HCT116, MCAS-S and MCAS-R 
cells. BEZ235 treatment induced significant increase in phospho-ERK levels, including 
MCAS-S cells (Fig. 6E), suggesting that ERK activation alone is not sufficient to induce 
MYC and YAP upregulation. Since ERK can regulate CREB (34), we examined whether 
ERK inhibition positively or negatively affects CREB expression in resistant HCT116 and 
MCAS-R cells. Combined treatment with BEZ235 and UO126 inhibited CREB expression 
(Fig. 6F), suggesting that ERK activation is required for CREB expression in the resistant 
cells, and that p38 and ERK have opposing roles in the regulation of CREB protein levels.
Given the opposing effects of p38 and ERK on BEZ235 responsiveness, we next assessed 
the degree to which these pathways contribute to the acquired and intrinsic resistance. To do 
this, we evaluated the effects of p38 inhibition in combination with BEZ235 and UO126 on 
survival and MYC and YAP upregulation in HCT116 and parental MCAS cells. Unlike in 
the MCAS cells, the addition of p38 inhibitor with BEZ235 did not result in any additional 
upregulation of MYC and YAP in HCT116 cells. However, the addition of p38 inhibitor to 
BEZ235 and UO126 treatment resulted in significantly improved cell survival and 
upregulation of MYC and YAP in both cell lines (Fig. 6G and H). These data imply that, 
even in a KRAS mutant background, the efficacy of combined inhibition of the PI3K/
mTOR- and MEK/ERK-pathways can be enhanced by the activation of p38, and conversely, 
that suppression of p38 can promote resistance through upregulation of MYC and YAP. 
Interestingly, combined treatment with p38 inhibitor and UO126 also resulted in improved 
cell survival (Figure 6G and H, Supplemental Fig. 4D), suggesting that activation of p38 
could also be an effective strategy to improve responsiveness to MEK/ERK inhibitors in 
KRAS mutant tumors.
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Taken together, these data support a model (Fig. 7) in which ERK and p38 play opposing 
roles in regulating the transcription factor CREB in tumor cells carrying mutations in the 
RAS/ERK-pathway, with ERK promoting CREB protein expression and p38 destabilizing it. 
Elevated CREB expression positively regulates YAP and MYC, allowing tumor cells to 
escape from proliferative suppression imposed by PI3K/mTOR inhibitors.
Discussion
Our data provide evidence for a previously unrecognized mode of drug resistance to PI3K/
mTOR inhibitors, which is observed in both acquired and intrinsically resistant cell lines, 
that involves re-wiring several parallel signaling pathways that coordinately promote 
induction of YAP and MYC, both of which are required for proliferation under conditions of 
PI3K/mTOR inhibition (Fig. 7). Furthermore, our data support a model (Fig. 7) in which 
both the ERK and p38/MAPK-pathways play critical, dichotomous roles in regulating 
resistance.
In cells that are sensitive to PI3K/mTOR inhibitors, drug treatment induces cytostasis (Fig. 
7A). This is likely mediated in part through p38 activation, which regulates cell cycle arrest 
at G1/S and G2/M checkpoints (28, 35). Our data indicate that suppression of p38 activity 
(Fig. 7C) allows resistant cells to escape proliferation inhibition induced by PI3K/mTOR 
inhibitors. This conclusion is supported by several findings: 1) p38-activation positively 
correlated with proliferation suppression by PI3K/mTOR inhibitors, 2) p38 activity was 
significantly lower in resistant cells compared to sensitive cells, and 3) p38 kinase inhibitors 
promoted proliferation, and YAP and MYC expression in the presence of BEZ235. 
Furthermore, p38 has been shown to regulate MYC expression at the post-transcriptional 
level (36), potentially explaining why MYC levels increased after combined BEZ235 and 
p38 inhibitor treatment. These data suggest that reduction in p38 activation in tumor cells 
could both release negative controls on proliferation as well as induce positive regulators of 
proliferation.
Our findings indicate that the mechanism of YAP upregulation upon p38 inhibition involves 
the transcription factor CREB. A recent report described an auto-regulatory feedback loop 
between p38, CREB and YAP whereby p38 inhibition leads to CREB stabilization (37). It 
was also shown that CREB binds to the YAP promoter and enhances its transcription (29, 
30). Indeed, we observed that overexpression of CREB increased YAP levels, and inhibition 
of p38 led to increased CREB and YAP expression, suggesting a functional link between 
p38, CREB and YAP. Furthermore, TCGA database analysis showed positive correlation 
between CREB and YAP expression in several tumor datasets, suggesting that these proteins 
could also be functionally coupled in patient tumors.
p38 is activated in response to cellular stress, such as DNA damage (reviewed in (27)), and 
also in response to inhibition of oncogenic kinases, such as EGFR, Bcr-Abl and Src (38). 
Although our data do not delineate how p38 activity is suppressed in the resistant cells, our 
results and that of others suggest that acute PI3K/mTOR inhibition leads to DNA damage 
and activation of DNA repair pathways (31, 32). However, in the resistant cells, p38 activity 
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was significantly suppressed, as were markers of DNA repair, suggesting that these cells 
have resolved the DNA damage stress leading to p38 activation.
Our study also implicates the RAS/ERK-pathway in promoting drug resistance and 
upregulation of YAP and MYC by three findings: 1) the strong correlation between 
mutations in KRAS/BRAF and resistance to PI3K/mTOR inhibition, 2) the suppression of 
YAP, MYC and CREB expression in resistant cells treated with a MEK inhibitor, and 3) the 
loss of resistance induced by down-regulation of mutant KRAS in HCT116 cells. These 
results suggest that the activity of MEK/ERK-pathway positively influences resistance, and 
that mutations in the RAS pathway provide a context in which a MYC-YAP resistance 
mechanism can be operative. Furthermore, ERK-pathway has been shown to stabilize MYC 
protein (39, 40), and the RAS-pathway has been implicated in YAP protein stabilization 
(41). However, YAP has been shown to promote resistance to RAF/MEK-targeted cancer 
therapies in RAS mutant tumors (42, 43) and to rescue cancer cells after KRAS loss (44, 
45), suggesting that YAP can be regulated at several levels to promote resistance to multiple 
targeted therapies.
Interestingly, both p38 and ERK-pathway activity, as well as reduced PI3K/AKT-pathway 
activity, have been linked to tumor cell dormancy (46–49). Results from the Aguirre-Ghiso 
group and others have shown that dormancy of tumor cells is dependent on the ratio of ERK 
and p38 activity, where a higher ERK/p38 ratio leads to cell cycle re-entry, whereas a higher 
p38/ERK ratio leads to tumor dormancy (50–53). Using a tumor model driven by HER2, 
Chodosh and colleagues showed that although withdrawal of this oncogene results in tumor 
regression, mice ultimately develop recurrent tumors that have become HER2 independent 
(54), suggesting the existence of residual dormant tumor cells. Although Notch signaling 
was implicated in maintenance of dormancy, its inhibition did not inhibit tumor re-growth 
(55), suggesting that another pathway regulates the growth of recurrent tumors.
Chronic PI3K/mTOR inhibition might induce a state resembling dormancy, perhaps through 
activation of p38 and cell cycle arrest (Fig. 7A). However, in the context of a mutated RAS/
ERK-pathway, and another unidentified factor that results in down-regulation of phospho-
p38, the balance between p38 and ERK is shifted, and ERK becomes more dominant under 
PI3K/mTOR inhibition. The reduction in p38 leads to an increase in CREB, YAP, and MYC 
levels, allowing a low level of proliferation resembling ‘awakening’ from dormancy (Fig. 7B 
and C). We speculate that while the acquired resistance is mainly driven by suppressed p38 
signaling, the intrinsic resistance would be more dependent on active ERK signaling. 
However, p38 inhibition in combination with PI3K/mTOR and MEK inhibitors resulted in 
improved fitness in both models, suggesting that activation of p38 would also benefit KRAS 
mutant tumors, a possibility worth exploring because of its translational implications.
In conclusion, these data suggest that in the absence of PI3K/mTOR signaling, MYC and 
YAP can orchestrate the required steps for cellular growth and proliferation normally driven 
by the PI3K/mTOR-pathways. We also demonstrate that activation of the RAS/ERK-
pathway alone is not sufficient to allow proliferation in the presence of chronic PI3K/mTOR 
inhibition, but also requires suppression of the stress-activated p38/MAPK. This implies that 
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tumors treated with PI3K/mTOR inhibitors enter a state similar to tumor dormancy, and can 
evade therapies aimed at targeting proliferating cells.
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Figure 1. 
MCAS cancer cells develop resistance to chronic PI3K/mTOR inhibition. (A) Top panel: 
Representative images of sensitive (MCAS-S) spheroids incubated with BEZ235 for 2d. 
Bottom panel: Representative images of resistant (MCAS-R) spheroids incubated with 1μM 
BEZ235 for 1y. Outgrowths of proliferating cells were detected in multiple structures 
(arrows). Scale bar: 200μm. (B) Left panel: Ki67 (red) and Laminin-5 (green) staining of 
MCAS-S and MCAS-R cells in BEZ235. Right panel: Cleaved-caspase-3 (red) and E-
cadherin (green) staining of resistant and sensitive cells. Scale bar: 25μm. (C–D) Cells were 
isolated from spheroid cultures, and similar numbers were re-plated in 3D. The MCAS-S 
and MCAS-R cells were incubated with DMSO (C), BEZ235 (0.5μM), Torin1 (0.5μM), or 
BEZ235 with Rapamycin (20nM) (D), proliferation was measured by cell counting. Data is 
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shown as total cell number and presented as mean SEM+/− from representative experiment 
of five. Statistical analysis: one-way ANOVA (p<0.001) and post-hoc Tukey HSD test. 
Pairwise p-values are shown (***p<0.005, **p<0.01, *p<0.05). (E) Western blot analysis of 
mTOR downstream-effectors from MCAS-R and MCAS-S cells in 3D treated with DMSO, 
BEZ235, Torin, or BEZ+Rapamaycin for 48h (MCAS-S) or 6d (MCAS-R).
Muranen et al. Page 16
Cancer Res. Author manuscript; available in PMC 2017 December 15.
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
Figure 2. 
MCAS-R cells exhibit increased MYC and YAP expression. (A) Heatmap from reverse 
phase protein array (RPPA) analysis showing proteins/phospho-proteins differentially 
expressed in MCAS-S and MCAS-R lines following DMSO and BEZ235 treatment 
(ANOVA, p<0.05). Data are median centered (red: greater than the median, green: less). For 
(A) and (B), the most discussed proteins in the manuscript are labeled in red font and 
marked with an asterisk. (B) RPPA analysis showing proteins differentially altered by 
BEZ235 in MCAS-S and MCAS-R cells in 3D. Heatmap visualizes relative differences in 
signal induced by BEZ235 in MCAS-R cells compared to BEZ235-treated MCAS-S cells. 
Proteins with significant (t-test, p<0.05) changes are shown. Values from BEZ235-resistant 
line are normalized to the average of BEZ235-sensitive line. (C) Western-blot validation of 
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the 3D protein arrays from (A–B). (D) Parental MCAS cells in 2D were transduced with 
pBABE-YAP and/or pWZL-MYC or plasmid controls, incubated with BEZ235 and counted. 
Fold change in cell number was calculated by normalizing the number of cells counted on 
Day 10 in BEZ235 compared to number of cells on Day 10 in their own DMSO controls. 
Lower panel shows validation of MYC/YAP expression. Statistical analysis: one-way 
ANOVA (p=6.1839e–14) and Tukey’s HSD test, which showed significant differences 
between all pairs **p<0.01. (E) YAP was knocked down with shRNAs (F5 and F8) in 
control or MYC-overexpressing MCAS cells and cell numbers were analyzed as in D. The 
proliferation graphs are a combined experiment of two, with triplicates in each. All data 
shown as mean SEM+/−. Statistical analysis: one-way ANOVA (p=1.8652e–14) with 
Tukey’s HSD test. **p<0.01.
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Figure 3. 
p38 and CREB regulate MYC and YAP. (A) phospho-p38 (T180/Y182) and p38 were 
probed by Western blot from MCAS-R and MCAS-S cells in DMSO or BEZ235 in 3D for 
6d. (B) Phase contrast images of parental MCAS cells cultured in 2D for 14 days in the 
presence of BEZ235 (BEZ), or pre-incubated with 5μM p38 inhibitor (SB203580) and then 
co-incubated with BEZ235. (C) Parental MCAS cells in 2D were treated with BEZ235 alone 
or BEZ235+SB203580 for 14d and cell numbers were counted on Day 14, graph represents 
total cell numbers. (D) Parental MCAS cells were incubated in 2D with DMSO, BEZ235 or 
combined BEZ235 and SB203580 for 14d, and lysates were probed for CREB, MYC, YAP, 
p-p38, and p-MAPKAPK by Western blot. (E) MCAS-S and MCAS-R cells were cultured in 
3D with BEZ235 and DMSO as in (A), lysed and probed for CREB. (F) Parental MCAS 
cells expressing wild-type CREB or control were cultured in BEZ235 in 2D. Cells were 
imaged at Day 12, and counted at indicated time-points. Graph shows fold change in cell 
number in BEZ235 on Day 8 compared to its own vector control in DMSO on Day 8. (G) 
Western blot analysis of cells from (F). Lysates were probed for CREB, MYC, and YAP. (H) 
Parental MCAS cells overexpressing WT-CREB and YAP shRNAs were cultured in BEZ235 
for the indicated time and [upper panel]: fold change in cell number over time in BEZ235 
normalized over cell number on Day 0, or [lower panel]: determined and normalized as in F. 
(I) Comparative analysis of YAP protein levels (RPPA-score) in CREB amplified vs. non-
amplified TCGA ovarian cancer data set. (J) Breast, endometrioid, colon and kidney cancer 
TCGA studies all show significant positive correlations between CREB and YAP mRNA 
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expression in human tumors. The proliferation graphs are a representative experiment of 
three, and triplicates were analyzed. All data shown as mean SEM+/−. Statistical analysis: 
Student’s t-test. *p<0.05, **p<0.01, ***p<0.005. Scale bars 100μm.
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Figure 4. 
Several intrinsically resistant tumor cell lines upregulate MYC and YAP in BEZ235. (A) 
Cell proliferation was measured for six cancer cell lines in the presence and absence of 
BEZ235 and represented as fold change in cell number in BEZ235 on Day 8 compared to 
the respective DMSO control on Day 8. (B) Western blot analysis of MYC and YAP in cell 
lines indicated in (A). (C) Cells were treated with BEZ235 for 8d and CREB levels were 
analyzed by Western blot. (D) MYC or YAP was knocked down by shRNAs (MYCsh: 
B6/B8; YAPsh: F5/F8) in HCT116 cells and change in cell number is shown as in (A) but 
each cell type is normalized to its own vector DMSO control. (E) HCT116 cells were 
transfected with pcDNA3-GFP or constitutively active p38 (pcDNA3-p38CA), treated with 
BEZ235 for 48h and cell proliferation was compared to proliferation in DMSO controls. All 
proliferation experiments were conducted with biological triplicates and repeated twice. All 
data shown as mean SEM+/−. Statistical analysis: Student’s t-test. ***p<0.005, **p<0.01.
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Figure 5. 
YAP and MYC are upregulated in mTOR inhibitor-treated xenograft tumors. (A–B) HCT116 
and (C–D) OVCAR5 cells were injected subcutaneously into five NOD-SCID mice and 
following tumor formation, mice were treated every 24h with PI3K/mTOR inhibitor 
GNE493 (10mg/kg) or vehicle for 8–14d. Tumors were harvested and stained for Ki67 (red) 
and MYC (B/D, green) or YAP (A/C, green). (E) Quantification of fluorescence intensity 
values of MYC and YAP staining in vehicle- and GNE493-treated tumors. Data shown as 
mean SEM+/−. Statistical analysis: Student’s t-test. ***p<0.005, **p<0.01, *p<0.05. Scale 
bar 50μm.
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Figure 6. 
Activated KRAS-pathway promotes resistance. (A) Cell lines were cultured in 2D with 
mTOR inhibitor Torin1 for 6d and relative growth in Torin1 compared to DMSO is shown. 
Cell lines with BRAF, RAS or NF1 mutation are indicated. *indicates cell line with 
activated RAS with no known mutation (56). (B) Relative cell number in Torin1 compared 
to DMSO in RAS-activated cells vs. non-RAS activated cells. (C) KRAS was knocked down 
in HCT116 cells and data is shown as fold change in cell number in BEZ235 on Day 6 
compared to each vectors DMSO control on Day 6. Lower panel shows validation of RAS 
knockdown. KRAS shRNA A7 resulted in cell death in DMSO and could not be used. 
Proliferation experiment was done twice with triplicates. (D) HCT116 cells were cultured in 
2D for 6 days in the presence of DMSO, BEZ235, or BEZ235 and 10μM UO126 and probed 
for MYC and YAP. (E) HCT116 in 2D and MCAS-R and -S cells in 3D were cultured for 
48h with DMSO or BEZ235 and probed for p-ERK. (F) MCAS-R and HCT116 cells were 
grown with DMSO, 0.5μM BEZ235, or BEZ235 and UO126 (10μM). Lysates were collected 
after 48h and probed for CREB and actin. (G) Parental MCAS cells and (H) HCT116 cells 
were cultured in 2D with indicated inhibitors and counted on Day 0 and Day 5 (HCT116) or 
Day 7 (MCAS). Fold change in cell number was calculated by comparing the cell number at 
the end of the experiment to that on Day 0. Experiments were repeated twice with triplicates. 
Cells were lysed on Day 2 (MCAS) and Day 4 (HCT116) and probed for MYC, YAP, and 
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actin. All data shown as mean SEM+/−. Statistical analysis: Student’s t-test. *p<0.05, 
**p<0.01, *** p<0.005.
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Figure 7. 
Model of signaling events leading to MYC and YAP upregulation. (A) In KRAS WT cells, 
inhibition of PI3K/mTOR leads to up-regulation of p38 through activated DNA damage 
pathway (and inhibition of CREB and MYC), and upregulation of receptor tyrosine kinases, 
with only a minor increase in p-ERK. (B) In KRAS mutant background, increased MEK/
ERK-signaling leads to slightly higher MYC levels, but high p-p38 still opposes MYC, 
CREB and YAP. (C) In KRAS mutant cells that have down-regulated p38 activity by 
relieving DNA damage response through an unknown mechanism, suppression of MYC and 
CREB is relieved and YAP is upregulated.
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